12/20
05:00 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/20
08:15 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $72.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $72.00 price target on the stock.
11/26
10:00 am
rna
Avidity Biosciences to Participate in Upcoming Investor Conference
Low
Report
Avidity Biosciences to Participate in Upcoming Investor Conference
11/26
07:51 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
Medium
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.
11/21
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
06:51 pm
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.
Medium
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.
11/13
08:06 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
High
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
11/12
07:00 am
rna
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Low
Report
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
11/9
09:50 am
rna
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/7
07:48 pm
rna
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
04:55 pm
rna
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]
11/7
04:05 pm
rna
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
Low
Report
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
11/6
11:24 am
rna
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]
Medium
Report
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]
10/31
09:00 am
rna
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
Medium
Report
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
10/31
08:35 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
10/30
09:25 am
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its price target raised by analysts at Chardan Capital from $60.00 to $65.00. They now have a "buy" rating on the stock.
Medium
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its price target raised by analysts at Chardan Capital from $60.00 to $65.00. They now have a "buy" rating on the stock.
10/30
08:00 am
rna
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
Low
Report
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
10/21
04:05 pm
rna
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/21
02:22 pm
rna
Avidity Biosciences, Inc. (NASDAQ: RNA) had its price target raised by analysts at TD Cowen from $56.00 to $78.00. They now have a "buy" rating on the stock.
Low
Report
Avidity Biosciences, Inc. (NASDAQ: RNA) had its price target raised by analysts at TD Cowen from $56.00 to $78.00. They now have a "buy" rating on the stock.
10/4
07:10 pm
rna
Why Avidity Biosciences Zoomed to a 12% Gain This Week [Yahoo! Finance]
Medium
Report
Why Avidity Biosciences Zoomed to a 12% Gain This Week [Yahoo! Finance]
10/4
11:09 am
rna
FDA lifts clinical hold on Avidity's lead antibody conjugate therapy trial [Yahoo! Finance]
Low
Report
FDA lifts clinical hold on Avidity's lead antibody conjugate therapy trial [Yahoo! Finance]
10/3
01:15 pm
rna
Avidity gets FDA partial clinical hold lifted on DM1 drug candidate [Seeking Alpha]
Low
Report
Avidity gets FDA partial clinical hold lifted on DM1 drug candidate [Seeking Alpha]
10/3
07:00 am
rna
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Low
Report
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
10/2
10:13 am
rna
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term [Seeking Alpha]
Low
Report
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term [Seeking Alpha]
9/25
09:00 am
rna
Avidity Biosciences to Participate in Upcoming Investor Conference
Medium
Report
Avidity Biosciences to Participate in Upcoming Investor Conference